Yayın: Observational study of immunosuppressive treatment patterns and outcomes in primary membranous nephropathy: A multicenter retrospective analysis
| dc.contributor.author | Artan, Ayse Serra | |
| dc.contributor.author | Mirioglu, Safak | |
| dc.contributor.author | Hocaoglu, Rabia Hacer | |
| dc.contributor.author | Turgutalp, Kenan | |
| dc.contributor.author | Boz, Saide Elif Gullulu | |
| dc.contributor.author | Eren, Necmi | |
| dc.contributor.author | Dincer, Mevlut Tamer | |
| dc.contributor.author | Uzun, Sami | |
| dc.contributor.author | Sahin, Gulizar | |
| dc.contributor.author | Kutlay, Sim | |
| dc.contributor.author | Cevher, Simal Koksal | |
| dc.contributor.author | Dheir, Hamad | |
| dc.contributor.author | Yilmaz, Murvet | |
| dc.contributor.author | Basturk, Taner | |
| dc.contributor.author | Tatar, Erhan | |
| dc.contributor.author | Kurultak, Ilhan | |
| dc.contributor.author | Özturk, Ramazan | |
| dc.contributor.author | Arikan, Hakki | |
| dc.contributor.author | Yadigar, Serap | |
| dc.contributor.author | Tunca, Onur | |
| dc.contributor.author | Turkmen, Kultigin | |
| dc.contributor.author | Elcioglu, Omer Celal | |
| dc.contributor.author | Kaya, Bulent | |
| dc.contributor.author | Karakan, Sebnem | |
| dc.contributor.author | Ayar, Yavuz | |
| dc.contributor.author | Gul, Cuma Bulent | |
| dc.contributor.author | Yazici, Halil | |
| dc.contributor.author | Özturk, Savas | |
| dc.contributor.buuauthor | GÜLLÜLÜ BOZ, SAİDE ELİF | |
| dc.contributor.department | Tıp Fakültesi | |
| dc.contributor.department | İç Hastalıkları Ana Bilim Dalı | |
| dc.contributor.department | Nefroloji Ana Bilim Dalı | |
| dc.contributor.researcherid | JCX-3921-2023 | |
| dc.date.accessioned | 2025-02-19T05:14:44Z | |
| dc.date.available | 2025-02-19T05:14:44Z | |
| dc.date.issued | 2024-10-01 | |
| dc.description.abstract | Background We evaluated the efficacy of different immunosuppressive regimens in patients with primary membranous nephropathy in a large national cohort. Methods In this registry study, 558 patients from 47 centers who were treated with at least one immunosuppressive agent and had adequate follow-up data were included. Primary outcome was defined as complete (CR) or partial remission (PR). Secondary composite outcome was at least a 50% reduction in estimated glomerular filtration (eGFR), initiation of kidney replacement therapies, development of stage 5 chronic kidney disease, or death. Results Median age at diagnosis was 48 (IQR: 37-57) years, and 358 (64.2%) were male. Patients were followed for a median of 24 (IQR: 12-60) months. Calcineurin inhibitors (CNIs) with or without glucocorticoids were the most commonly used regimen (43.4%), followed by glucocorticoids and cyclophosphamide (GC-CYC) (39.6%), glucocorticoid monotherapy (25.8%), and rituximab (RTX) (9.1%). Overall remission rate was 66.1% (CR 26.7%, PR 39.4%), and 59 (10.6%) patients reached secondary composite outcome. Multivariate logistic regression showed that baseline eGFR (OR 1.011, 95% CI: 1.003-1.019, p = 0.007), serum albumin (OR 1.682, 95% CI: 1.269-2.231, p < 0.001), and use of RTX (OR 0.296, 95% CI: 0.157-0.557, p < 0.001) were associated with remission rates; whereas only lower baseline hemoglobin was significantly associated with secondary composite outcome (OR: 0.843, 95% CI: 0.715-0.993, p = 0.041). CYC use was significantly associated with higher remission (OR 1.534, 95% CI: 1.027-2.290, p = 0.036). Conclusions Higher baseline eGFR and serum albumin levels correlated with increased remission rates. Remission rates were lower in patients treated with RTX, while those on GC-CYC showed higher rates of remission. Due to the study's retrospective nature and multiple treatments used, caution is warranted in interpreting these findings. | |
| dc.identifier.doi | 10.1186/s12882-024-03784-8 | |
| dc.identifier.eissn | 1471-2369 | |
| dc.identifier.issue | 1 | |
| dc.identifier.scopus | 2-s2.0-85205527502 | |
| dc.identifier.uri | https://doi.org/10.1186/s12882-024-03784-8 | |
| dc.identifier.uri | https://bmcnephrol.biomedcentral.com/articles/10.1186/s12882-024-03784-8 | |
| dc.identifier.uri | https://hdl.handle.net/11452/50512 | |
| dc.identifier.volume | 25 | |
| dc.identifier.wos | 001326720700004 | |
| dc.indexed.wos | WOS.SCI | |
| dc.language.iso | en | |
| dc.publisher | BMC | |
| dc.relation.journal | Bmc Nephrology | |
| dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi | |
| dc.rights | info:eu-repo/semantics/openAccess | |
| dc.subject | Follow-up | |
| dc.subject | Methylprednisolone | |
| dc.subject | Cyclophosphamide | |
| dc.subject | Chlorambucil | |
| dc.subject | Rituximab | |
| dc.subject | Trial | |
| dc.subject | Cyclosporine | |
| dc.subject | Tacrolimus | |
| dc.subject | Steroids | |
| dc.subject | Receptor | |
| dc.subject | Membranous nephropathy | |
| dc.subject | Immunosuppression | |
| dc.subject | Chronic kidney disease | |
| dc.subject | Remission | |
| dc.subject | Science & technology | |
| dc.subject | Life sciences & biomedicine | |
| dc.subject | Urology & nephrology | |
| dc.title | Observational study of immunosuppressive treatment patterns and outcomes in primary membranous nephropathy: A multicenter retrospective analysis | |
| dc.type | Article | |
| dspace.entity.type | Publication | |
| local.contributor.department | Tıp Fakültesi/İç Hastalıkları Ana Bilim Dalı/Nefroloji Ana Bilim Dalı | |
| local.indexed.at | WOS | |
| local.indexed.at | Scopus | |
| relation.isAuthorOfPublication | 63440f8c-694e-4dff-b787-86d3c7cc2bc6 | |
| relation.isAuthorOfPublication.latestForDiscovery | 63440f8c-694e-4dff-b787-86d3c7cc2bc6 |
Dosyalar
Orijinal seri
1 - 1 / 1
